Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?

Table 1 Demographic and clinical data of the study groups

	Control group (n = 27)	NPDR group (n = 10)	PDR group (n = 13)	P-value
Hypertension, n (HT+/HT-)	11/16	4/6	6/7	0.939^a
Sex, n (F/M)	13/14	3/7	7/6	0.496^a
Age (years) (mean ± SD)	65.74 ± 7.17	66.70 ± 12.37	67.85 ± 8.93	0.778^b

F Female, M Male, n Count, HT(+) Hypertension positive group, HT( ̶) Hypertension negative group, SD Standard deviation Note: ^aChi-Square test, ^bOne Way ANOVA test

ISSN: 1471-2415